0 620

Cited 109 times in

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

DC Field Value Language
dc.contributor.author이동기-
dc.contributor.author허용민-
dc.date.accessioned2016-02-04T11:19:08Z-
dc.date.available2016-02-04T11:19:08Z-
dc.date.issued2015-
dc.identifier.issn0142-9612-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140158-
dc.description.abstractMulti-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An in vitro study of cell viability and mRNA expression levels and an in vivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.-
dc.description.statementOfResponsibilityopen-
dc.format.extent763~774-
dc.relation.isPartOfBIOMATERIALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/pharmacology-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHBiliary Tract Neoplasms/drug therapy*-
dc.subject.MESHBiliary Tract Neoplasms/pathology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDrug Carriers*-
dc.subject.MESHHumans-
dc.subject.MESHHyaluronan Receptors/drug effects*-
dc.subject.MESHNanoparticles*-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.titleCo-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorIlkoo Noh-
dc.contributor.googleauthorHyun-Ouk Kim-
dc.contributor.googleauthorJihye Choi-
dc.contributor.googleauthorYuna Choi-
dc.contributor.googleauthorDong Ki Lee-
dc.contributor.googleauthorYong-Min Huh-
dc.contributor.googleauthorSeungjoo Haam-
dc.identifier.doi10.1016/j.biomaterials.2015.03.006-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02723-
dc.contributor.localIdA04359-
dc.relation.journalcodeJ00312-
dc.identifier.eissn1878-5905-
dc.identifier.pmid25890771-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0142961215002768-
dc.subject.keywordBiliary cancer-
dc.subject.keywordCD44 targeting-
dc.subject.keywordCombined cancer therapy-
dc.subject.keywordGemcitabine-
dc.subject.keywordPaclitaxel-
dc.subject.keywordPolymeric prodrug-
dc.contributor.alternativeNameLee, Dong Ki-
dc.contributor.alternativeNameHuh, Yong Min-
dc.contributor.affiliatedAuthorLee, Dong Ki-
dc.contributor.affiliatedAuthorHuh, Yong Min-
dc.rights.accessRightsnot free-
dc.citation.volume53-
dc.citation.startPage763-
dc.citation.endPage774-
dc.identifier.bibliographicCitationBIOMATERIALS, Vol.53 : 763-774, 2015-
dc.identifier.rimsid53935-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.